SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

MAMO.X is trending as social media buzz points to a potential breakout, with community members highlighting a cup and handle formation. Talk centers around the anticipation of its integration into the Base App and the possibility of new users being exposed to the crypto. Some traders are drawing comparisons to other tokens, while others express excitement about its potential.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU.X is trending as its community rallies around its real-world applications, including merchandise and energy drinks, emphasizing its dedication to building an enduring brand. The community's strong IRL presence and growing holder count are key talking points, with many expressing bullish sentiment about its long-term potential. Despite market fluctuations, the focus remains on community growth and the upcoming new website.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as buyers fuel a rally following the company's acquisition of anti-coagulant assets, with bulls eyeing higher highs and breakout energy feeling strong. Community members are discussing the potential for an upside breakout with strong volume as the company advances its pipeline of cardiovascular products. The healthcare technology niche has a thin volume trading.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard ($MA) is trending due to a mix of options activity and broader market analysis, with community members pointing out both bullish and bearish signals. Discussions include unusual options flow, analyst ratings, and potential impacts from tariffs and competition in the payment processing space. Some are questioning if stablecoins or general economic uncertainty will affect MA's long-term growth.

TON Strategy Co. engages in platform development. The firm's Software-as-a-Service (SaaS) platform is based on its proprietary interactive video technology and consists of a suite of sales enablement business software products offered on a subscription basis. The company was founded by Rory J. Cutaia on November 27, 2012 and is headquartered in Las Vegas, NV.

TON Strategy Co.

TON Strategy ($TONX) is trending due to its strategic pivot towards accumulating Toncoin and integrating with Telegram, sparking community debate about its long-term viability and potential within the blockchain ecosystem. While some traders express skepticism and point to the company's past performance, others highlight the potential of leveraging Telegram's massive user base for crypto adoption. Discussions also involve recent share repurchases and insider activity.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks ($ANET) is trending amid ongoing discussions about its potential in the AI-driven data center market, with analysts highlighting strong growth prospects and key partnerships. Community members are actively evaluating entry points and discussing potential upside, particularly given the company's alignment with AI and data center trends. Option activity and analyst target updates contribute to the increased attention on the stock.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck ($MRK) is trending due to a mix of factors, including potential pipeline expansion with its recent acquisition of Verona Pharma and anticipation surrounding its upcoming earnings report. Community discussions also highlight Keytruda's performance and the looming patent expiration, leading to speculation about future acquisitions to bolster their portfolio. Some traders are eyeing potential breakout opportunities above $85.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is trending as the community discusses potential short squeezes, driven by a high short interest and upcoming dividend payouts. Bullish sentiment is fueled by Citigroup's recent price target increase and observed unusual options activity. Some traders are also pointing to the company's real estate assets and potential for a turnaround, while others highlight the partnership with Sephora as a growth driver.

Freddie Mac engages in the provision of housing finance system solutions. It operates through the Single-Family and Multifamily segments. The Single-Family segment is involved in purchase, securitization, and guarantee of single-family loans, investments, and management of single-family mortgage credit risk and market risk. The Multifamily segment focuses on purchase, securitization, and guarantee of multifamily loans, investments, securities, and management of multifamily mortgage credit risk and market risk. The company was founded on July 24, 1970 and is headquartered in McLean, VA.

Federal Home Loan Mortgage Corp

Freddie Mac

Freddie Mac ($FMCC) is trending as investors react to rising mortgage rates and speculation around a potential IPO. Community discussions revolve around Trump's involvement, the structure of a deal, and potential dilution. Some investors see a buying opportunity, while others are expressing concern regarding conservatorship.

McDonald's Corp. engages in the operation and franchising of restaurants. It operates through the following segments: U.S., International Operated Markets, and International Developmental Licensed Markets and Corporate. The U.S. segment focuses its operations on the United States. The International Operated Markets segment consists of operations and the franchising of restaurants in Australia, Canada, France, Germany, Italy, the Netherlands, Russia, Spain, and the U.K. The International Developmental Licensed Markets and Corporate segment consists of developmental licensee and affiliate markets in the McDonald’s system. The firm's products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, several chicken sandwiches, Chicken McNuggets, wraps, McDonald's Fries, salads, oatmeal, shakes, McFlurry desserts, sundaes, soft serve cones, pies, soft drinks, coffee, McCafe beverages, and other beverages. The company was founded by Raymond Albert Kroc on April 15, 1955, and is headquartered in Oak Brook, IL.

McDonald`s Corp

McDonald's Corp

McDonald's is trending as traders react to analyst upgrades and potential catalysts like the return of snack wraps. The community is closely watching for a breakout above the $300 resistance level, while also considering potential headwinds like changing consumer spending habits and anti-American sentiment. Discussions also highlight McDonald's efforts to innovate its menu, expand its digital presence, and attract value-conscious customers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.The company reported Q4&nbsp;earnings per share (EPS) of $5.32, beating the $5.08 consensus estimate, while revenue came in at $13.53 billion, topping Wall Street’s $13.43 billion forecast.&nbsp;Sales of its blockbuster GLP-1 drugs Zepbound and Mounjaro surged but came in slightly below expectations, weighed down by lower realized prices.&nbsp;Mounjaro generated $3.53 billion in revenue, a 60% jump from the prior year but short of analysts’ $3.62 billion estimate. Zepbound posted $1.91 billion in sales, missing the $1.98 billion forecast.&nbsp;This marks the second consecutive quarter where both drugs have fallen short of estimates, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">CNBC</a>.Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.&nbsp;CEO David Ricks called 2024 a highly successful year, highlighting major clinical readouts for tirzepatide in treating chronic diseases tied to obesity, billions in manufacturing expansion, and the launch of Alzheimer’s drug Kisunla and dermatitis medication Ebglyss as key drivers of long-term growth.&nbsp;“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” he added.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_sentiment_and_message_volume_Feb_6_premarket_0e4b15d3e8.png" alt="Eli Lilly sentiment and message volume Feb 6 premarket.png" width="1318" height="324"><figcaption>Eli Lilly sentiment and message volume Feb 6 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, Eli Lilly was among the top 10 trending tickers ahead of Thursday’s opening, with sentiment turning more bullish.&nbsp;Optimistic traders pointed to the earnings beat and expected continued strength, with one eyeing a move past $900.&nbsp;<stembedurl>https://stocktwits.com/Zukio/message/603106677</stembedurl>Another said hedge funds and institutional investors would likely drive the&nbsp;actual move during market hours.<stembedurl>https://stocktwits.com/nat9co/message/603108641</stembedurl>For 2025, Eli Lilly expects EPS between $22.50 and $24.00, compared to the $22.69 consensus estimate, and projects revenue between $58 billion and $61 billion, surpassing Wall Street’s $58.91 billion forecast.&nbsp;The company is ramping production to meet soaring demand, estimating it will manufacture at least 1.6 times the number of incretin doses in the first half of 2025 compared to a year ago.&nbsp;Lilly also announced plans to report late-stage data for its next-generation obesity drug retatrutide later this year, ahead of schedule.As of Wednesday’s close, <a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> was up nearly 8% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Equity

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.


Roundhill Investments Surpasses $4 Billion AUM Milestone

Roundhill Investments Surpasses $4 Billion AUM Milestone Roundhill Investments Surpasses $4 Billion AUM Milestone PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Roundhill...

Eli Lilly &amp; Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-falls-on-q4-weight-loss-drug-sales/chG8mwrRVc">plunge</a> — the worst session for the stock in nearly four years.&nbsp;The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance, with significant misses in sales for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.However, several Wall Street analysts expressed optimism, suggesting the dip could offer an attractive entry point for investors.Leerink noted Lilly lowered its Q4 revenue guidance by 5% but issued a 2025 revenue forecast 2% above its consensus, according to The Fly. The brokerage maintained its 'Outperform' rating, citing long-term growth potential and a promising pipeline.BofA Securities reiterated a 'Buy' rating with a $997 price target,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/eli-lilly-bofa-says-buy-the-dip-after-shares-slide-on-q4-miss-3813128">according</a> to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player in the "diabesity" market with significant growth opportunities.JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity, highlighting Lilly's strong 2025 positioning, expanded market presence, and anticipated 60% growth in sellable doses of incretins in the first half of 2025.Mizuho's Jared Holz&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=eli+lilly+mizuho&amp;oq=eli&amp;gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDsyBggCEEUYOzITCAMQLhiDARjHARixAxjRAxiABDIGCAQQRRg5MgYIBRBFGDwyBggGEEUYPDIGCAcQRRg90gEINjAxMGowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">told</a> CNBC that "some of the supply commentary from the company makes a lot of sense" and highlighted the nascent stage of the obesity market. However, he flagged valuation as a concern, with Lilly trading at 32 times 2025 earnings estimates—higher than most large-cap pharma peers.Retail message volume on Stocktwits about Lilly jumped over 240% on Tuesday.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_15_premarket_8c6741e2bb.png" alt="LLY sentiment and message volume Jan 15 premarket.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 15 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>Heading into Wednesday, sentiment on the platform remained 'bullish,' as watchers took cues from analyst optimism and kept faith in long-term prospects for Lilly's weight-loss and diabetes drugs remain intact.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly's stock</a> is down 4.5% year-to-date but has gained over 16% in the past 12 months. The company will report fourth-quarter and full-year results next month.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

Eli Lilly Recovers Premarket As Analysts Defend Stock After Tuesday’s Slide, Retail Bullish

Shares of Eli Lilly &amp; Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the&nbsp;stock’s worst day since March 15, 2021.&nbsp;The decline followed a disappointing fourth-quarter revenue outlook update, particularly from its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.The company now forecasts full-year revenue of about $45 billion, down from its previous range of $45.4 billion-$46 billion and below the consensus of $45.55 billion.&nbsp;Fourth-quarter revenue is expected to be approximately $13.5 billion, falling short of the $13.93 billion consensus.&nbsp;Sales of Mounjaro totaled $3.5 billion, below the $4.4 billion estimate, while Zepbound brought in $1.9 billion, missing expectations of $2.14 billion.CEO David A. Ricks attributed the shortfall to slower-than-expected growth in the U.S. incretin market, compounded by lower year-end channel inventory. Incretins like GLP-1 are used in diabetes and obesity drugs such as Mounjaro and Zepbound.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_14_082f836502.png" alt="LLY sentiment and message volume Jan 14.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 14 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>However, retail sentiment on Stocktwits stayed ‘extremely bullish,’ with the ticker climbing to the top five trending symbols list amid a spike in message volume.&nbsp;Many retail investors considered the dip an overreaction, expressing optimism for 2025 projections and hinting they were buying the dip.<stembedurl>https://stocktwits.com/ChrisH76/message/599965534</stembedurl><stembedurl>https://stocktwits.com/NastyPelosi/message/599965487</stembedurl><stembedurl>https://stocktwits.com/OldFagGuy/message/599960901</stembedurl><stembedurl>https://stocktwits.com/JackCoLu/message/599959582</stembedurl>Lilly expects continued growth for Mounjaro and Zepbound in 2025, supported by expanded manufacturing capacity and new market launches.&nbsp;The company plans to increase production of tirzepatide by at least 60% in the first half of 2025 compared to the same period in 2024.Lilly anticipates revenue contributions from new drugs, including oncology treatment Jaypirca, dermatitis medication Ebglyss, Crohn’s disease therapy Omvoh, and Alzheimer’s drug Kisunla.&nbsp;Additionally, the company is pursuing approvals for new indications of existing medicines and potential launches, such as imlunestrant for metastatic breast cancer.Lilly expects its experimental weight-loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-01-13/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says?sref&amp;">revealed</a> during an interview with Bloomberg TV at the JPMorgan Healthcare Conference in San Francisco on Monday. Data on the pill is expected by mid-2025.Lilly’s stock has gained over 16% in the past year but is down nearly 5% in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections

The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.  

Shares of Eli Lilly &amp; Co. (<a class="mention" data-mention="$LLY" data-symbol-id="LLY" href="https://stocktwits.com/symbol/LLY" target="_blank">$LLY</a>) and Novo Nordisk A/S (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) climbed in Tuesday’s premarket trading after the Biden administration announced a proposal to provide Medicare and Medicaid coverage for obesity drugs.In a statement released early Tuesday, the White House said, "The proposed rule would be implemented at the same time as a comprehensive agenda to lower the costs of drugs, including the drug price negotiation program and increased market competition."An analysis by the Department of Health and Human Services (HHS) found that obesity drug pricing in the international market is much lower than in the U.S., the&nbsp; White House release said.&nbsp;"It’s unacceptable that Americans – especially those without insurance coverage for these drugs — are forced to pay so much more for life-saving medications," it added.Currently, anti-obesity medications are given Medicare and Medicaid coverage&nbsp;only&nbsp;for certain conditions like diabetes.&nbsp;"Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease, and help an estimated 3.4 million Americans with Medicare," the release said.The Biden administration expects the coverage to reduce out-of-pocket costs of these prescription drugs by as much as 95% for some enrollees. It sees about 4 million adult Medicaid enrollees to gain new access to these medications.The new proposal will override the previous legislation passed 20 years ago, prohibiting Medicare coverage for weight-loss drugs.The proposal has to be endorsed by the incoming Trump administration to become a law.&nbsp; The proposition looks&nbsp;like&nbsp;a tall order as President-elect Donald Trump has nominated&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-names-anti-vaxxer-robert-kennedy-as-health-and-human-services-secretary-here-s-what-it-means-for-healthcare-stocks/cJ4F4ofRfY">Robert Kennedy Jr.</a>, who is very vocal with his opposition to these medications, to lead HHS.&nbsp;Novo Nordisk and Lilly are leaders in the weight-loss drug category, with their Wegovy and Zepbound, respectively. Both are injectable formulation of drugs belonging to a class of medications called GLP-1 agonists. These work by reducing the appetite, slowing the release of food from the stomach and increasing the feeling of fullness after eating.&nbsp;Novo Nordisk’s Wegovy sales jumped 79% year-over-year in the third quarter to $2.5 billion and Lilly’s Zepbound sales came in at $1.26 billion.On Stocktwits, retail sentiment toward both Novo Nordisk and Lilly remained stuck at "neutral."In premarket trading, as of 7:48&nbsp;a.m. ET, Novo Nordisk shares climbed 2.62% to $107.30, and Lilly jumped 4.90% to $792.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

The Biden administration expects the coverage to reduce out-of-pocket costs of obesity drugs by as much as 95% for some enrollees.

Eli Lilly, Novo Nordisk Shares Climb Premarket As Biden Administration Mulls Medicare, Medicaid Coverage For Obesity Drugs: Retail Unmoved

The new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare. 

Danish diabetes drug maker Novo Nordisk A/S ($NVO), which shot to prominence with its Wegovy weight-loss drug, reported Wednesday strong sales and earnings growth for the third quarter.Novo Nordisk reported third-quarter net profit 27.30 billion Danish Kroner ($3.92 billion), up 21% year-over-year (Y-o-Y), as sales also rose by a similar magnitude to 71.31 billion Danish Kroner (DKK).&nbsp;The top-line, however, came in below the 72.3 billion DKK-consensus estimate, according to Reuters, amid softer-than-expected diabetes drug sales.Wegovy sales jumped 79% YoY to 17.30 DKK ($2.5 billion), ahead of the 15.9 billion DKK forecast by analysts.Wegovy is a once-weekly injectable formulation of Novo Nordisk’s diabetes drug semaglutide, marketed as Ozempic. It was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.Novo Nordisk’s diabetes franchise fetched sales of 47.94 billion DKK, up 13% YoY.Looking ahead, the company said it expects 2024 sales to rise at a currency-neutral rate of 23-27%, and operating profit to grow by 21%-27%.The company is now evaluating a two-drug combo treatment candidate by the name CagriSema, for obesity, and a late-stage readout for the drug is expected later this year.As of 10:53 am ET, the stock fell 1.91% to $108.03.<figure class="image"><a href="https://stocktwits.com/symbol/NVO"><img style="aspect-ratio:646/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nvo_sentiment_0ac0560a3f.png" alt="nvo-sentiment.png" width="646" height="140"></a><figcaption>NVO sentiment and message volume November 6, 2024, &nbsp;as of 10:53 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment toward Novo Nordisk stock was 'bullish' (72/100), with message volume rising to ‘extremely high’ level.A retailer said on the Stocktwits platform that he was buying the dip.<stembedurl>https://stocktwits.com/Sasquamch/message/591414857</stembedurl>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/exact-sciences-reports-double-miss-for-q3/cJ4RtWFR9Y">Exact Sciences Stock Plunges After Q3 Miss, Guidance Cut: Retail Stays Mostly Positive</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Novo Nordisk Q3 earnings and revenue climbed by double-digit percentages.

Novo Nordisk Stock Falls Despite Strong Q3 Weight-Loss Drug Sales: Retail Shrugs Off Weakness

: Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.

Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.


Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) PR Newswire NEW YORK, May 21, 2024 OZEM provides exposure to the rapidly...

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OZEM News

OZEM Roundhill GLP-1 & Weight Loss ETF